Citius Oncology shares rise 11.48% premarket after announcing U.S. commercial launch of LYMPHIR for CTCL.

Citius Oncology (CTOR) surged 11.48% in premarket trading following the announcement of its U.S. commercial launch of LYMPHIR™, a novel cancer immunotherapy for cutaneous T-cell lymphoma. The launch, reported by PR Newswire two days prior, marks a key milestone after months of strategic preparations, including partnerships with McKesson and Cencora for distribution, integration of AI tools to enhance commercial operations, and securing $9.0 million in capital. The market appears to view the launch as a catalyst for revenue growth and operational scalability, reversing prior declines linked to concerns over profitability and regulatory hurdles. The timing of the news aligns with the stock’s upward movement, suggesting strong investor optimism about LYMPHIR’s market potential and Citius Oncology’s execution capabilities.